Thursday, November 19, 2026

A Little Ditty: From Anthropic Billions to a No-Name Penny Stock with a Fight and a Purpose

  


Market Talk

Yesterday, was about the potential billions surrounding Anthropic and the excitement of a possible blockbuster IPO.

Today, I'm going in a completely different direction. Far away from the Wall Street excitement to a little 45-cent biotech underdog, ONCY

A company fighting cancer, fighting financial troubles, and fighting for recognition.

And that brings me to today's Stock Talk.

Stock Talk

ONCY: The Cinderella Man Is Still Fighting

Years ago, I compared Oncolytics Biotech (ONCY) to James J. Braddock, the real-life Cinderella Man.

Unlike Rocky Balboa, Braddock wasn't a fictional character. He was a struggling fighter during the Great Depression, taking his lumps, trying to feed his family, and refusing to quit.

The 2005 movie Cinderella Man, starring Russell Crowe and Paul Giamatti, captured that struggle beautifully.

Before continuing, I invite readers to watch these three short clips. This is what fighting cancer may feel like to the fighters with advancing cancer.

Cinderella Man — Braddock Beats Lasky (The Grin)

Cinderella Man — Run It Again

Cinderella Man — Braddock vs. Baer

Now back to ONCY. This little underdog has taken its lumps over the years. Financial pressures have mounted, but somehow it's still in the ring.

The small REO 022 colorectal cancer study, using ONCY's Pelareorep (Pela) in combination with approved cancer drugs, produced some impressive numbers:


  • Objective Response Rate (ORR): 33% versus historical benchmarks of approximately 6–11%.

  • Median Progression-Free Survival (PFS): 16.6 months versus approximately 5.7 months.

  • Median Overall Survival (OS): 27 months versus approximately 11.2 months.

Encouraging results, particularly the survival numbers, but still a small fight in a long battle. These comparisons were against historical studies, not a randomized head-to-head trial.

Now comes REO 033, a randomized trial, with an initial tumor-response update expected before year's end. This could be a much bigger fight.

Meanwhile, after years and tears of smaller trials, some remarkable results have emerged, including two complete responses in advanced anal cancer patients who had already undergone previous treatments.

Recently, Coherus Oncology agreed to supply its FDA -approved checkpoint inhibitor for a planned anal cancer study, expected to be sponsored by a major U.S. cancer institution.

Still, Wall Street largely looks elsewhere. ONCY remains a penny stock, short on money, and its longtime shareholders have taken their lumps too.

Could impressive REO 033 results bring Big Pharma into the picture? Maybe someone with deep pockets to help finish what ONCY started?

I don't know.

A Note to This Story: ONCY has not yet identified the major U.S. cancer institution expected to sponsor its upcoming anal cancer study. But who could it be?

Three possibilities come to mind:

  1. MD Anderson Cancer Center — Dr. Van Morris.

  2. Memorial Sloan Kettering Cancer Center — Dr. Neil Segal.

  3. Northwestern University's Lurie Cancer Center — Dr. Deva Mahalingam.

All three doctors have served on ONCY's Scientific Advisory Board. These are educated guesses, not confirmed arrangements.

But there is something much bigger than a stock price here. Patients with advancing cancer, some running out of treatment options, stepping into clinical trials with hope for another chance.

The stage seems to be getting set. Much like Braddock's story somewhere in the middle, before anybody knew how it would end.

There are no guarantees of victory. Not in the stock market, and certainly not in the fight against cancer.

But the fight goes on.

And I hope and pray for improved outcomes for the fighters.

Stay Watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.